In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHS Scotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within a particular health board because of available services and preferences for alternative medicines.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The ADTC, Grampian Area Drug and Therapeutics Committee, is responsible for advising NHS Grampian health board on all aspects of the use of medicines.

Medicines routinely available within NHS Grampian are usually included in the Grampian Joint Formulary. The formulary is a list of medicines for use in the health board that has been agreed by the ADTC in consultation with local clinical experts. It offers a choice of medicines for healthcare professionals to prescribe for common medical conditions. A formulary can help improve safety as prescribers are likely to become more familiar with the medicines in it and also helps make sure that standards of care are consistent across the health board.

How does the health board decide which new medicines to make routinely available for patients?

The ADTC in a health board will consider national and local guidance before deciding whether to make a new medicine routinely available.

What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland, it looks at:
  - how well the medicine works,
  - which patients might benefit from it,
  - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
  - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence Multiple Technology Appraisals (NICE MTAs) are applicable in Scotland.

What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in a health board.

Why is a particular medicine not routinely available in NHS Grampian?

- This is usually because the medicine is not recommended for use in NHS Scotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences as to which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board consider whether to add new medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

What happens if a particular medicine is not routinely available in NHS Grampian?

- If a medicine is not routinely available and not included in the Grampian Joint Formulary and there are no suitable alternatives on the formulary, a healthcare professional can request to prescribe a medicine that is not on the formulary if they think you will benefit from using it. All health boards have procedures in place to consider requests when a healthcare professional feels a medicine that is not on the formulary would be right for a particular patient.

The table below lists NHS Grampian's latest decisions on medicines.

If you need more information on medicines decisions in NHS Grampian, please email gram.formularyteam@nhs.scot.



This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) 551116 or (01224) 552245.

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
belzutifan 40mg film-coated tablets (Welireg®)	2587	Treatment of adults with von Hippel-Lindau (VHL) disease who require therapy for VHL associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable or undesirable.	Routinely available in line with national guidance, SMC 2587 https://scottishmedicines.org.uk/media/7868/belzutifan-welireg-final-sept-2023-for-website.pdf	21/01/2025
Biktarvy® 30mg/120mg/15mg film-coated tablet (bictegravir/emtricitabine/ tenofovir alafenamide)	2760	Treatment of human immunodeficiency virus-1 (HIV-1) infection in paediatric patients at least 2 years of age and weighing at least 14kg to less than 25kg without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.	Not routinely available as not recommended for use in NHS Scotland, SMC 2760 https://scottishmedicines.org.uk/media/8859/bictegravir-emtricitabine-tenofovir-alafenamide-biktarvy-non-sub-final-dec-2024-for-website.pdf	21/01/2025
ciclosporin 0.9mg/mL eye drops solution in single-dose container (Cequa®)	2739	Treatment of moderate-to-severe Dry Eye Disease (keratoconjunctivitis sicca) in adult patients who have not responded adequately to artificial tears. **SMC restriction**: severe keratitis in adult patients with Dry Eye Disease.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/01/2025
crovalimab 340mg solution for injection/infusion (Piasky®)	2728	As monotherapy for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40kg and above with paroxysmal nocturnal haemoglobinuria (PNH) in patiens: - with haemolysis with clinical symptom(s) indicative of high disease activity. - who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months. **SMC restriction**: under the advice of the national PNH service	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/01/2025
Cymbalta® 30mg, 60mg capsules (duloxetine)		In adults for the treatment of major depressive disorder, diabetic peripheral neuropathic pain and generalised anxiety disorder.	This medicine is now withdrawn from use/discontinued	21/01/2025

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
danicopan 50mg, 100mg film-coated tablets (Voydeya®)	2675	As an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia. **SMC restriction**: under the advice of the national PNH service.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/01/2025
daratumumab 1,800mg solution for subcutaneous injection (Darzalex®)		In combination with bortezomib, lenalidomide and dexamethasone for the treatment of adults with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.	Routinely available in line with local guidance	21/01/2025
daratumumab 20mg/mL concentrate for solution for infusion (Darzalex®)		As licensed.	Not routinely available as there is a local preference for alternative medicines	21/01/2025
desmopressin 360micrograms/mL oral solution (Demovo®)		In adults, adolescents and children over 5 years for the treatment of: - central diabetes insipidus - primary nocturnal enuresis in patients with normal capacity to concentrate urine	Routinely available in line with local guidance	21/01/2025
durvalumab 50mg/mL concentrate for solution for infusion (Imfinzi®)	2677	In combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, is indicated for the treatment of adults with resectable (tumours ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known EGFR mutations or ALK rearrangements.	Not routinely available as not recommended for use in NHS Scotland, SMC 2677 https://scottishmedicines.org.uk/media/8810/durvalumab-imfinzi-final-nov-2024-for-website.pdf	21/01/2025
Emerade® 150mg, 300mg, 500mg solution for injection in pre-filled pen (adrenaline)		For emergency treatment of severe allergic reactions (anaphylaxis) caused by allergens in foods, medicines, insect stings or bites and other allergens as well as triggered by exercise or unknown causes.	This medicine is now withdrawn from use/discontinued	21/01/2025

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
epcoritamab 4mg/0.8mL concentrate for solution for injection, 48mg solution for injection (Tepkinly®)	2632	As monotherapy for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.	Routinely available in line with national guidance, SMC 2632 https://scottishmedicines.org.uk/media/8387/epcoritamab-tepkinly-final-may-2024-amended-050624-for-website.pdf	21/01/2025
etrasimod 2mg film-coated tablets (Velsipity®)	2655	For the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.	Decision deferred to future meeting	21/01/2025
fosdenopterin 9.5mg powder for solution for injection (Nulibry®)	2624	For the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A.	Not routinely available in NHS Grampian. If local need identified, contact the Pharmacist Team Leader/Principal Pharmacist – Supply (ARI)	21/01/2025
glofitamab 1mg/mL concentrate for solution for infusion (Columvi®)	2614	As monotherapy for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.	Routinely available in line with national guidance, SMC 2614 https://scottishmedicines.org.uk/media/8388/glofitamab-columvi-final-may-2024-amended-050624-for-website.pdf	21/01/2025
Insulatard® Penfill 100units/mL suspension for injection in cartridge (human isophane insulin)		For the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.	This medicine is now withdrawn from use/discontinued	21/01/2025
iptacopan 200mg hard capsules (Fabhalta®)	2676	As monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia. **SMC restriction**: under the advice of the national PNH service.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/01/2025
Lecigon® 20mg/mL /5mg/mL / 20mg/mL intestinal gel (levodopa/carbidopa monohydrate/ entacapone)	2507	Treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results.	Not routinely available as not recommended for use in NHS Scotland, SMC 2507 https://scottishmedicines.org.uk/media/8807/levodopa-carbidopa-entacapone-lecigon-final-jan-2023-amended-071124-for-website.pdf	21/01/2025

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Metanium® Nappy Rash Ointment (titanium dioxide/ titanium peroxide/ titanium salicylate)		As a treatment for nappy rash.	This medicine is now withdrawn from use/discontinued	21/01/2025
Neutrogena® T/Gel® therapeutic shampoo 2% (coal tar extract)		For the treatment of seborrhoeic dermatitis of the scalp, dandruff and scalp psoriasis.	This medicine is now withdrawn from use/discontinued	21/01/2025
Norinyl-1® 1mg/50microgram tablets (norethisterone/mestranol)		For oral contraception.	This medicine is now withdrawn from use/discontinued	21/01/2025
Plenvu® powder for oral solution		In adults for bowel cleansing prior to any procedure requiring a clean bowel.	Routinely available in line with local guidance	21/01/2025
risankizumab 180mg, 360mg solution for injection in cartridge, 600mg concentrate for solution for infusion (Skyrizi®)	2686	For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/01/2025
rozanolixizumab 140mg/mL solution for injection (Rystiggo®)	2761	As an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.	Not routinely available as not recommended for use in NHS Scotland, SMC 2761 https://scottishmedicines.org.uk/media/8853/rozanolixizumab-rystiggo-non-sub-final-dec-2024-for-website.pdf	21/01/2025
Ryeqo® 40mg/1mg/0.5mg film-coated tablets (relugolix/ estradiol/ norethisterone acetate	2666	In adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/01/2025
sirolimus 2mg/g gel (Hyftor®)	2710	For the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/01/2025

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Strontium ranelate Aristo® 2g granules for oral suspension		For treatment of severe osteoporosis: - In postmenopausal woman - In adult men at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance. In postmenopausal women, strontium ranelate reduces the risk of vertebral and hip fractures.	This medicine is now withdrawn from use/discontinued	21/01/2025
tenecteplase 5,000 units (25mg) powder for solution for injection (Metalyse®)	2697	In adults for the thrombolytic treatment of acute ischaemic stroke within 4.5 hours from last known well and after exclusion of intracranial haemorrhage.	Routinely available in line with national guidance, SMC 2697 https://scottishmedicines.org.uk/media/8727/tenecteplase-metalyse-abbreviated-final-oct-2024-for-website.pdf	21/01/2025
ublituximab 150mg concentrate for solution for infusion (Briumvi®)	2731	Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. **SMC restriction**: treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/01/2025
vamorolone 40mg/mL oral suspension (Agamree®)	2721	Treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/01/2025
vibegron 75mg film-coated tablets (Obgemsa®)	2696	Symptomatic treatment of adult patients with overactive bladder (OAB) syndrome.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/01/2025
Yentreve® 20mg, 40mg capsules (duloxetine)		In adults for treatment of moderate to severe stress urinary incontinence in women.	This medicine is now withdrawn from use/discontinued	21/01/2025
zanubrutinib 80mg hard capsules (Brukinsa®)	2684	As monotherapy for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/01/2025